Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), announced that the U.S. Food and Drug Admini...
Ensifentrine is a first-in-class, selective, dual inhibitor of the enzymes phosphodiesterase 3 and 4 ("PDE3" and "PDE4") combining bronchodilator and non-s...
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the de...
he Phase 1, first-in-human, multicenter clinical study seeks to characterize the safety, potential efficacy and evaluate possible biomarkers of response to...
Perfuse Therapeutics, a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular diseases announced today that the ...
The purpose of this trial is to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared with that of placebo in 20-30...
PathoVax LLC ("PathoVax"), a biotech company focused on developing a universally preventative Human Papillomavirus (HPV) vaccine - "RGVax", today announced...
Søren Tulstrup, President and CEO, Hansa Biopharma said, "This phase 2 study of imlifidase in GBS is an important next step in understanding the rol...
TandemAI today announced the release of TandemViz™ 1.0, the company’s proprietary web-based platform that provides its growing roster of drug d...
-Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced dosing of the first pati...
"The FDA's accelerated approval program has provided patients with cancer earlier access to novel treatments that can be practice changing," said Richard P...
SARS-CoV-2 spike protein (B.1.351 strain) vaccine is the first and only protein-based variant COVID-19 booster vaccine approved in Great Britain and the ...
© 2025 Biopharma Boardroom. All Rights Reserved.
